Loading…
← CockpitCompetitor Analysis › SPARC.NS Sun Pharma Advanced Research Co. Ltd.Open in the cockpit ↗

Sun Pharma Advanced Research Co. Ltd.SPARC.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum neutral 59
Mkt cap
$660M
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$5.41M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.3%
Hurdle
n/a
no reverse DCF
Close · INR₹190.12
1D-1.6%
1W-9.7%
1M+2.7%
3M-1.5%
6M+5.8%
YTD+41.4%
1Y+43.0%
ATR %4.8%
Beta1.63
52w lowhigh34.2% off high

What Sun Pharma Advanced Research does

Employees: 466

Sun Pharma Advanced Research at a glance

Size Sun Pharma Advanced Research (SPARC.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $660M, the 751st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹190.12 on 18 Nov 2026.

Performance Over six months the shares gained 5.8%, against -14.2% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 3,141.0% over the last twelve months (peer median +8.6%); the operating margin is 84.3% (peer median 10.0%).

Valuation It trades at 2.5× enterprise value to sales against a peer median of 2.7× (9th cheapest of 17).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026SPARC.NS 104Peer median 89
Six months, rebased to 100: Sun Pharma Advanced Research against the median of its 20 peers (local-currency closes).

Sun Pharma Advanced Research financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹19.3B₹18.8B₹718M₹755M₹2.39B
Revenue growth—+2,518%-5%-68%—
Gross profit₹17.8B₹17.1B-₹1.34B-₹1.24B₹821M
EBITDA₹16.4B₹16.1B-₹3.22B-₹3.99B-₹2.12B
Net income₹16.4B₹15.5B-₹3.43B-₹3.87B-₹2.23B
Free cash flown/a-₹2.97B-₹3.65B-₹4.35B-₹904M
Capital expendituren/a₹238M₹103M₹265M₹154M
Total debt₹24.4M₹5.59B₹2.69B₹612M₹157M

Quarterly statements and history in the cockpit →

Sun Pharma Advanced Research competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%FDCANNX688488PHIL688658INNOVACAP60035100056630001641230009154985300878ABUSNVCTBCAX301211OLMA4105SPARC.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Sun Pharma Advanced Research is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%0×5×10×15×FDC688488PHIL688658INNOVACAP60035100056641234985300878ABUS301211SPARC.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sun Pharma Advanced Research is the large dot.

Sun Pharma Advanced Research competitors and peer comparison

How Sun Pharma Advanced Research compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sun Pharma Advanced Research against its 20 peers (data as of 18 Nov 2026)
MeasureSPARC.NSPeer medianRank in peer set
1-month return+2.7%-5.2%4th highest of 21
6-month return+5.8%-14.2%5th highest of 21
Distance from 52-week high-34.2%-38.7%10th highest of 21
Revenue growth (TTM)+3,141.0%+8.6%highest of 17
Operating margin84.3%10.0%highest of 17
EV / Sales2.5×2.7×9th cheapest of 17
EV / EBITDA3.0×9.4×3rd cheapest of 8
Net debt / EBITDA-0.8×-1.3×4th most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%1.6×-8.3%-2.8%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%

Questions

Which companies are Sun Pharma Advanced Research's closest peers?
The cockpit's peer set: FDC (FDC.NS), Annexon (ANNX), Jiangsu Aidea Pharmaceutical (688488.SS), Philogen (PHIL.MI), Youcare Pharmaceutical (688658.SS), Innova Captab (INNOVACAP.NS), Yabao Pharmaceutical (600351.SS), Hainan Haiyao (000566.SZ).
Is Sun Pharma Advanced Research expensive compared with its peers?
On ev / sales it trades at 2.5× against a peer median of 2.7×, 9th cheapest of 17 in its peer set.
How has Sun Pharma Advanced Research stock performed?
Over six months to 18 Nov 2026 the shares returned +5.8% against -14.2% for the median peer; over one year +43.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.